Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Starbucks is looking to reignite consumer interest by teaming up with Disney for a limited-edition Minnie Mouse-themed ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) shot up 1.7% during mid-day trading on Thursday . The company traded as high as $792.56 and last traded at $786.15. 3,476,307 shares traded hands ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

HBW Advisory Services LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.7% during the 4th quarter, according to its most recent disclosure with the SEC. The ...